© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions
Posted 18th February 2020

Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions

Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions
Title21

Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. From reporting to analytics, Title21 provides all the critical data at your fingertips so the right person has the right data at the right time to make the right decisions. This allows Medical Technologists, Technical and Medical Directors to focus on higher-value work, and ultimately the patient, rather than chasing down paperwork and people.

Earlier this year, Title21 was selected as the Most Outstanding Cell Therapy Software Provider for 2019 by AI’s Global Excellence Award. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider.

Since their inception, Tile21’s Cloud and onpremise software manages critical patient, product and process data for cell and gene therapy, immunotherapy and regenerative medicine to ensure quality, compliance and traceability. Programs that implement Title21 solutions find they can scale more effectively to treat more patients and can also translate products more quickly and efficiently from bench to bedside, delivering the latest innovative therapies to patients faster and more safely.

Title21 has served FDA-regulated life science companies for many years with quality management software, so Title21’s experience has been of great service to the cell therapy segment. “Our technology is extremely flexible due to its configurability on the front end. That means that we can maintain a single code base while meeting each cancer center or cell manufacturers’ specific requirements.”

“Every team member at Title21 is dedicated to supporting the lifesaving work that health care providers do each and every day.”

“At Title21, we partner with the largest and top-rated cancer hospitals – placing the patient first. One of our greatest testimonials we hear often is that our customers want us to continue to solve more of their challenges with our technology. They ask Title21 to help provide solutions through technology to increase the quality, safety and efficiency of their programs.” Current Title21 customers have a strong influence on the technology roadmap to add value to patient therapeutic care and quality. Analytics and business intelligence are also important and play a significant role in the future of developing new cures and protocols more quickly and efficiently. Cell and gene therapy is a dynamic market and the protocols are changing rapidly as they are improved and refined.

Moving forward, the future looks bright for the team at Title21 as they continue to provide exceptional services and award-winning solutions to hospitals and biotech firms. “Our passion is to serve the many patients and their families who face life-threatening diseases by supporting the leading healthcare institutions and biotech companies with powerful tools that help them deliver innovative treatments to their patients. Every team member at Title21 is dedicated to supporting the lifesaving work that health care providers do each and every day” remarks Fischer.

Bringing the interview to a close, Lynn signs off by revealing the exciting plans which lie in the pipeline for the business, which includes their ambitions to further expand the business in the years to come, especially with the advancements in immunotherapy technology.

Categories: Innovation


You Might Also Like
Read Full PostRead - Eye Icon
3 Top Environmental Consulting Companies in 2025
News
21/02/20253 Top Environmental Consulting Companies in 2025

Businesses want answers on how to be the most sustainable in their niche. Many shareholders know the journey to implement eco-friendly practices demands time and attention, so it makes sense that everyone wants to delegate the beginning of this process to an e

Read Full PostRead - Eye Icon
The Best Innovations for the Best Metalwork
Innovation
08/08/2022The Best Innovations for the Best Metalwork

Working in one of the most demanding markets in the world, Retech has become a global leader in metallurgical processing equipment supply.

Read Full PostRead - Eye Icon
8 Signs You Might Need an Employee Settlement Agreement
News
04/08/20258 Signs You Might Need an Employee Settlement Agreement

8 Signs You Might Need an Employee Settlement Agreement Once the workplace environment turns from annoying to definitely unpleasant, you can usually be sure that there is a more serious issue involved. Maybe it seems like you are being pushed out, or you sudde

Read Full PostRead - Eye Icon
Leveraging AI for Fraud Detection and Risk Assessment in the FinTech
News
22/01/2024Leveraging AI for Fraud Detection and Risk Assessment in the FinTech

While ChatGPT become lazy recently, denying to perform basic tasks, and making excuses on why it shouldn’t do, what was required, it is still hard to deny that machine learning models can bring many advantages to any technological solution, and FinTech i

Read Full PostRead - Eye Icon
How Does SaaS Financing Work in 2022?
Finance
02/09/2022How Does SaaS Financing Work in 2022?

The SaaS segment is replete with startups hoping to become the next big thing, and eventually achieve worldwide success.

Read Full PostRead - Eye Icon
Empowering Your Accounting Software with AI Capabilities
Finance
03/01/2024Empowering Your Accounting Software with AI Capabilities

According to a recent study by KPMG, over 59% of large organizations already use AI in their financial, accounting, and tax departments and about 29% plan to implement AI-powered software within the next 12 months.

Read Full PostRead - Eye Icon
The Key  to Unlocking Success: Post-Merger Integration  – Synergy and Value
Strategy
15/04/2015The Key to Unlocking Success: Post-Merger Integration – Synergy and Value

Bryan Brighton is the Regional Director at Merrill DataSite. Based in their European Headquarters, London, Bryan supports the International growth of the Merrill DataSite business. He spoke to AI about how he delivers success for his company.

Read Full PostRead - Eye Icon
How to Prepare Your Business for Expansion: A Quick Guide
News
03/02/2023How to Prepare Your Business for Expansion: A Quick Guide

There’s no doubt that starting a new business can be very rewarding, but there are also challenges that come with it. Making sure that your business is thriving and taking the next steps will be vital to your success.

Read Full PostRead - Eye Icon
6 Trends That Every Engineer Needs to Know in 2021
News
29/10/20216 Trends That Every Engineer Needs to Know in 2021

A few years back, who thought that flying cars would be a reality–it was a distant and long-overhauled dream. But the rapid rise of technology and engineering concepts is making the impossible turn into "I'm possible" and flipping the current technology on i



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow